$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2017
[Lowest Price Guaranteed: $3,500]

Published by Global Markets Direct: 31 Oct 2017 | 143082 | In Stock
Related Topics: Alzheimer's Disease , Bladder Cancer , Breast Cancer , Cancer , Cirrhosis , Colorectal Cancer , Gas , Hepatitis , Hypertension , Immunology , Infectious Disease , Lung Cancer , Multiple Myeloma , Myeloma , Ophthalmology , Pancreatic Cancer , Parkinson's Disease , Prostate Cancer , Protein , Pulmonary , Respiratory , Steatohepatitis

Introduction

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2017

Summary

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Caspase 3 - Pipeline Review, H2 2017, outlays comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Caspase-3 is a caspase protein encoded by the CASP3 gene. It interacts with caspase-8 and caspase-9. It cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. It cleaves and activates caspase-6, -7 and -9. It is involved in the cleavage of huntingtin. It triggers cell adhesion in sympathetic neurons through RET cleavage. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Genito Urinary System And Sex Hormones, Cardiovascular, Central Nervous System, Infectious Disease, Hematological Disorders, Immunology, Metabolic Disorders, Ophthalmology, Respiratory and Toxicology which include indications Prostate Cancer, Colorectal Cancer, Glomerulonephritis, Inflammatory Bowel Disease, Age Related Macular Degeneration, Alzheimer's Disease, Autoimmune Hepatitis, Bladder Cancer, Breast Cancer, Chemotherapy Induced Neutropenia, Diabetic Retinopathy, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Hepatitis C, Hepatocellular Carcinoma, Huntington Disease, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Transplant Rejection, Metastatic Brain Tumor, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myocardial Infarction, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Parkinson's Disease, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis, Renal Failure, Solid Tumor, Spinal Cord Injury, Stroke, Traumatic Brain Injury, Urinary Tract Cancer and Zika Virus Infections.

Furthermore, this report also reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)

- The report reviews Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics and enlists all their major and minor projects

- The report assesses Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2017

  • Table of Contents

    Table of Contents 2

    List of Tables 5

    List of Figures 5

    Introduction 6

    Global Markets Direct Report Coverage 6

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Overview 7

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Development 8

    Products under Development by Stage of Development 8

    Products under Development by Therapy Area 9

    Products under Development by Indication 10

    Products under Development by Companies 13

    Products under Development by Universities/Institutes 17

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Assessment 19

    Assessment by Mechanism of Action 19

    Assessment by Route of Administration 21

    Assessment by Molecule Type 23

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Companies Involved in Therapeutics Development 25

    BeyondSpring Pharmaceuticals Inc 25

    Conatus Pharmaceuticals Inc 25

    New World Laboratories Inc 26

    Novartis AG 26

    Pharmedartis GmbH 27

    Sanofi 27

    Shire Plc 28

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Drug Profiles 29

    1G3-Cu - Drug Profile 29

    Product Description 29

    Mechanism Of Action 29

    R&D Progress 29

    BaxB-01 - Drug Profile 30

    Product Description 30

    Mechanism Of Action 30

    R&D Progress 30

    BaxG-03 - Drug Profile 32

    Product Description 32

    Mechanism Of Action 32

    R&D Progress 32

    BaxM-159 - Drug Profile 34

    Product Description 34

    Mechanism Of Action 34

    R&D Progress 34

    emricasan - Drug Profile 35

    Product Description 35

    Mechanism Of Action 35

    R&D Progress 35

    emricasan - Drug Profile 43

    Product Description 43

    Mechanism Of Action 43

    R&D Progress 43

    flavokawain A - Drug Profile 44

    Product Description 44

    Mechanism Of Action 44

    R&D Progress 44

    Fusion Protein to Activate CASP3 and CASP9 for Oncology - Drug Profile 45

    Product Description 45

    Mechanism Of Action 45

    R&D Progress 45

    HaA-4 - Drug Profile 46

    Product Description 46

    Mechanism Of Action 46

    R&D Progress 46

    IDN-7314 - Drug Profile 47

    Product Description 47

    Mechanism Of Action 47

    R&D Progress 47

    MBRI-001 - Drug Profile 48

    Product Description 48

    Mechanism Of Action 48

    R&D Progress 48

    NWL-53 - Drug Profile 49

    Product Description 49

    Mechanism Of Action 49

    R&D Progress 49

    plinabulin - Drug Profile 50

    Product Description 50

    Mechanism Of Action 50

    R&D Progress 50

    Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile 56

    Product Description 56

    Mechanism Of Action 56

    R&D Progress 56

    Small Molecule to Activate Caspase-3 for Oncology - Drug Profile 57

    Product Description 57

    Mechanism Of Action 57

    R&D Progress 57

    Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile 58

    Product Description 58

    Mechanism Of Action 58

    R&D Progress 58

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Dormant Products 59

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Discontinued Products 62

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Product Development Milestones 63

    Featured News & Press Releases 63

    Oct 26, 2017: BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia 63

    Oct 23, 2017: BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline 63

    Oct 20, 2017: Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting 64

    Oct 18, 2017: BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco 64

    Oct 18, 2017: EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC 65

    Aug 14, 2017: Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis 65

    Jul 06, 2017: China FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention 66

    Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC 67

    Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference 68

    Jun 15, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San Diego 69

    May 08, 2017: BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017 69

    Apr 25, 2017: BeyondSpring Enrolls First US Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention 70

    Mar 22, 2017: BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017 71

    Mar 20, 2017: BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia 72

    Mar 14, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo 73

    Appendix 75

    Methodology 75

    Coverage 75

    Secondary Research 75

    Primary Research 75

    Expert Panel Validation 75

    Contact Us 75

    Disclaimer 76

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

143082 | GMDHC1117TDB

Number of Pages

76

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H1 2018
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic ...
27 Feb 2018 by Global Markets Direct USD $3,500 More Info
Caspase 3 (CPP32, Apopain or YAMA) Activators -Pipeline Insights, 2017
DelveInsight’s, “Caspase 3 (CPP32, Apopain or YAMA) Activators-Mechanism of action Insights, 2017”, ...
01 Sep 2017 by Delve Insight USD $1,250 More Info
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2017
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic ...
29 Aug 2017 by Global Markets Direct USD $3,500 More Info
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2017
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ce...
18 Jul 2017 by Global Markets Direct USD $3,500 More Info
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2017
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2017SummaryAccor...
20 Jun 2017 by Global Markets Direct USD $3,500 More Info
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H1 2017
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22....
13 Jun 2017 by Global Markets Direct USD $3,500 More Info
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H1 2017
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 ...
30 May 2017 by Global Markets Direct USD $3,500 More Info
Caspase 3 (CPP32, Apopain or YAMA) Activators -Pipeline Insights, 2017
DelveInsight’s, “Caspase 3 (CPP32, Apopain or YAMA) Activators-Pipeline Insights, 2017”, report prov...
30 May 2017 by Delve Insight USD $1,250 More Info
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2016
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ce...
21 Dec 2016 by Global Markets Direct USD $3,500 More Info
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2016
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic ...
16 Nov 2016 by Global Markets Direct USD $3,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2017 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...